First transdermal oxycodone nears Phase III as Phosphagenics cues up next opioid target
This article was originally published in Scrip
With formulation issues for its lead therapeutic product now resolved, Phosphagenics looks set to apply for the approval of a pivotal clinical program for its first-in-class transdermal oxycodone product well within the first half of next year.
You may also be interested in...
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.